secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001628280-24-036589
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics reports net loss of $22.8M in H1 2024; cash $93.4M; AVTX-009 Phase 2 enrollment on track for H2
--------------------------------------------------------------------------------

- Cash and cash equivalents $93.4M as of June 30, 2024; expected cash runway into 2027.
- Net loss for six months ended June 30, 2024 was $22.8M, compared to $18.1M in same period 2023.
- AVTX-009 IND for hidradenitis suppurativa active; Phase 2 LOTUS Trial first patient enrollment expected H2 2024.
- Appointed Dr. Mittie Doyle as CMO and Paul Varki as CLO; Q2 2024 net income of $98.5M from warrant liability fair value change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024036589/0001628280-24-036589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024036589/avtx-20240812.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-036589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer